• Exceeded FY25 revenue and EBITDA guidance
• Achieved positive operating and free cashflow
• Strengthened operational foundations and leadership team
• Secured FDA clearance for Rest Assure compliance monitoring system

SomnoMed Ltd delivered a transformative year in FY25, with the company exceeding its revenue and EBITDA guidance. Revenue grew 22% to $111.5 million, while EBITDA reached $9.2 million, a significant turnaround from the prior year. Importantly, the company also achieved positive operating and free cashflow. These results demonstrate SomnoMed's ability to execute consistently, scale responsibly, and grow profitably. The company made significant improvements across its operations, including a 50% increase in manufacturing capacity, reduced turnaround times, and the elimination of its backlog. This operational transformation was enabled by the strengthening of the company's leadership team, with the addition of several experienced executives across key functions such as manufacturing, product development, finance, and quality. The board also welcomed Andrew Price, who brought extensive global supply-chain expertise. A key highlight for the year was the FDA clearance of SomnoMed's Rest Assure system, the first oral appliance globally to receive clearance for its compliance monitoring capabilities. This represents an important milestone for the company and the oral appliance therapy category, as it supports clinicians, payors, and patients with meaningful data. Looking ahead, SomnoMed is focused on embedding the gains made in FY25, while continuing to invest in operational efficiency, manufacturing capacity, and the successful execution of the Rest Assure clinical program. The company has reaffirmed its FY26 guidance, which includes revenue of $119-$126 million and EBITDA of $10-$12 million.

FY26 revenue of $119-$126 million, EBITDA of $10-$12 million, and capex of $6-$8 million.

SomnoMed remains focused on its ambition to make oral appliance therapy a mainstream treatment for obstructive sleep apnea. The company will continue to deliver consistently strong clinical outcomes, innovate, and improve the patient experience. With shifting consumer trends, increased awareness, and growing interest in alternatives to CPAP, the opportunity for oral appliance therapy continues to expand.